Papers

1

Total Citations

56

H-Index

1

About

Dr. Aoshuang Cheng is a leading clinical researcher in gynecologic oncology, with a primary focus on optimizing surgical outcomes for early-stage cervical cancer. Her most impactful work challenges the prevailing shift toward minimally invasive surgery (MIS) for radical hysterectomy. In her highly cited 2019 protocol paper (56 citations), Dr. Cheng critically addresses the landmark LACC trial and U.S. epidemiological data, which revealed unexpectedly poorer survival outcomes with MIS compared to open surgery. She designed a phase III multicentre randomized controlled trial in China to rigorously compare the efficacy of different surgical approaches on clinical and survival outcomes. This protocol is pivotal, as it aims to resolve the urgent clinical equipoise and potential risks introduced by the widespread adoption of MIS. By establishing a robust, prospective framework, Dr. Cheng’s contribution provides essential, high-quality evidence to guide surgical decision-making, directly impacting patient safety and long-term prognosis. Her work underscores a commitment to evidence-based practice in a rapidly evolving surgical landscape, making her a key voice in the ongoing debate over the optimal treatment for early-stage cervical cancer.

Research Focus

Key Achievements

1
H-Index
1
Papers
56
Total Citations
56
Avg Citations/Paper
🏆 Most Cited Paper
Efficacy of different surgical approaches in the clinical and survival outcomes of patients with early-stage cervical cancer: protocol of a phase III multicentre randomised controlled trial in China
56 citations · 2019
📈 Most Prolific Year: 2019 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago